Vinblast
Generic Name
Vinblastine Sulfate
Manufacturer
Example Pharma Ltd.
Country
Global, e.g., USA, India
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| vinblast 10 mg injection | ৳ 850.00 | N/A |
Description
Overview of the medicine
Vinblastine is a vinca alkaloid used in chemotherapy to treat various types of cancer. It works by inhibiting cell division.
Uses & Indications
Dosage
Adults
Initial dose: 3.7 mg/m² IV, followed by weekly increments of 1.85 mg/m² up to a maximum of 18.5 mg/m² or until WBC count drops to 3000 cells/mm³. Common weekly maintenance dose: 6 mg/m² IV.
Elderly
No specific dose adjustment based solely on age; monitor for comorbidities and reduced organ function.
Renal_impairment
No specific dose adjustment for mild to moderate renal impairment; use with caution. For severe impairment, close monitoring is advised.
Hepatic_impairment
Dose reduction necessary in patients with significant hepatic dysfunction. E.g., for bilirubin >3 mg/dL, reduce dose by 50%.
How to Take
Administer intravenously only. Fatal if given intrathecally. Should be given as a bolus over 1 minute or a short infusion. Avoid extravasation due to irritant nature.
Mechanism of Action
Vinblastine binds to tubulin, inhibiting microtubule formation. This leads to disruption of the mitotic spindle, arresting cell division at metaphase and inducing apoptosis.
Pharmacokinetics
Onset
Rapid due to IV administration.
Excretion
Excreted mainly via feces (bile) and to a lesser extent via urine.
Half life
Triphasic elimination with a terminal half-life of approximately 20-25 hours.
Absorption
Administered intravenously, hence 100% bioavailability. Rapidly distributed into tissues.
Metabolism
Primarily metabolized in the liver by CYP3A enzymes.
Side Effects
Contraindications
- •Severe leukopenia (WBC < 3000 cells/mm³)
- •Bacterial infection (untreated)
- •Significant hepatic impairment
- •Pregnancy and lactation
Drug Interactions
Bleomycin
May enhance pulmonary toxicity when used in combination (e.g., MOPP/ABVD regimens).
Phenytoin
Vinblastine may decrease phenytoin levels.
Live vaccines
Avoid due to immunosuppressive effects of vinblastine.
CYP3A inhibitors (e.g., Ketoconazole, Erythromycin)
May increase vinblastine levels and toxicity.
Storage
Store intact vials refrigerated at 2°C to 8°C (36°F to 46°F). Protect from light. Do not freeze.
Overdose
Symptoms include severe myelosuppression, neurotoxicity, nausea, vomiting, and paralytic ileus. Management is supportive, including blood transfusions, granulocyte colony-stimulating factors, and antiemetics.
Pregnancy & Lactation
Pregnancy Category D: May cause fetal harm. Avoid during pregnancy. Lactation: It is unknown whether vinblastine is excreted in human milk; due to potential for serious adverse reactions in nursing infants, breastfeeding is contraindicated.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 2-3 years for unopened vials when stored as recommended. After reconstitution, use within 24 hours.
Availability
Hospitals, Specialized Oncology Centers, Pharmacies
Approval Status
Approved for various oncologic indications
Patent Status
Off-patent
WHO Essential Medicine
YesAlternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in